Post-IPO Equity - Genkyotex
Investment Firm
Overview
Genkyotex develops innovative drugs to block the NOX enzymes that produce oxygen radicals.
Announced Date
Feb 06, 2020
Funding Type
Post Ipo Equity
Highlights
Location
Switzerland, Europe
Social
Investor Lead
N/A
Participant Investors
1
No investment info available on this profile
Round Details and Background
Genkyotex raised $5380790 on 2020-02-06 in Post-IPO Equity
Genkyotex develops innovative drugs to block the NOX enzymes that produce oxygen radicals.
Company Funding History
8
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Jul 09, 2012 |  Series C - Genkyotex | 4 | - | 25.6M |
| May 24, 2011 | Series C - Genkyotex | 5 | - | 20.4M |
| Jan 30, 2006 | Seed Round - Genkyotex | 1 | - | 1.6M |
| May 05, 2008 | Series A - Genkyotex | 1 | - | 4.0M |
Recent Activity
There is no recent news or activity for this profile.